Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20145653 | 0.86 | TAAR1 (0.41) | TAAR1IDO1 | |
| SCHEMBL21184400 | 0.82 | TAAR1 (0.59) | TAAR1HTR2AHRH4HRH3 | |
| SCHEMBL3178484 | 0.79 | TAAR1 (0.57) | TAAR1HTR2AIDO1 | |
| SCHEMBL30176770 | 0.79 | TAAR1 (0.57) | TAAR1HTR2AIDO1 | |
| SCHEMBL2758514 | 0.78 | ALDH1A1 (0.39) | GABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL3176975 | 0.77 | TAAR1 (0.55) | TAAR1HTR2AIDO1 | |
| SCHEMBL14992081 | 0.77 | TAAR1 (0.41) | TAAR1HRH4HRH3 | |
| SCHEMBL20425554 | 0.76 | TAAR1 (0.60) | TAAR1HTR2A | |
| SCHEMBL12378777 | 0.76 | TAAR1 (0.60) | TAAR1HTR2A | |
| SCHEMBL15456512 | 0.76 | ABCB11 (0.40) | GABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558577-B1 | SUBSTITUTED 4-PHENYL-PIPERIDIN-AMIDES AS TACHYKININ ANTAGONISTS AND SEROTONIN REPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | ALVARO GIUSEPPE | 2009-07-30 | — | — | US | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1622871-A1 | CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004099143-A1 | CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | TAAR1 13/4885HTR2A 116/4885GABRA1 1347/4885 |
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | SLC6A4, OPRL1, HCRTR1 | TAAR1 64/4885HTR2A 65/4885GABRA1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.